X-Ray Study Investigating The Safety And Efficacy Of SD-6010 In Subjects With Osteoarthritis Of The Knee

Back to Search
Print
Bookmark Trial

NCT01438918

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Knee Osteoarthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
40 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Subjects aged >= 40 years Diagnosed with knee OA (ACR definition of OA) Radiographic evidence of OA in the study knee

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


A diagnosis of any other rheumatic disease Current conditions in the study knee that would
confound efficacy Selected, traditional clinical safety and laboratory parameters

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Knee OsteoarthritisA Dose-Ranging Study Of Valdecoxib 5 Mg, 10 Mg, And 20 Mg Once Daily Versus Placebo In Patients With Osteoarthritis Of The Knee (Japan) NCT00650624
  1. Funabashi, Chiba
  2. Sakura, Chiba
  3. Chikushi-gun, Fukuoka
  4. Iizuka, Fukuoka
  5. Kurume, Fukuoka
  6. Yame, Fukuoka
  7. Chitose, Hokkaido
  8. Sapporo, Hokkaido
  9. Kamakura, Kanagawa
  10. Yokohama, Kanagawa
  11. Isahaya, Nagasaki
  12. Hirakata, Osaka
  13. Kanzaki-gun, Saga
  14. Karatsu, Saga
  15. Ogi-gun, Saga
  16. Itabashi-ku, Tokyo
  17. Setagaya-ku, Tokyo
  18. Shinjuku-Ku, Tokyo
  19. Taito-ku, Tokyo
  20. Yoyogi Shibuya-ku, Tokyo
  21. Saga,
  22. Tokyo,
ALL GENDERS
20 Years+
years
MULTIPLE SITES
Knee OsteoarthritisEfficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (Europe) NCT00630929
  1. Bad Muender,
  2. Beckum,
  3. Berlin,
  4. Berlin,
  5. Berlin,
  6. Berlin,
  7. Ostseebad Damp,
  8. Schwerin,
  9. Stade,
  10. Tostedt,
  11. Weener,
  12. Barcelona,
  13. Barcelona,
  14. Cadiz,
  15. Guadalajara,
  16. Madrid,
  17. Madrid,
  18. Madrid,
  19. Oviedo,
  20. Sevilla,
  21. Valencia,
  22. Chelmsly Wood, Birmingham
  23. Truro, Cornwall
  24. Chorley, Lancs
  25. Liverpool, Lancs
  26. Cannock, Mid Staffordshire
  27. Addlestone, Surrey
  28. Huddersfield,
  29. London,
  30. London,
  31. Manchester,
  32. Newcastle Upon Tyne,
  33. Wigan,
ALL GENDERS
40 Years+
years
MULTIPLE SITES
Knee OsteoarthritisA Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee NCT00981357
  1. Miami, Florida
  2. Miami, Florida
  3. Overland Park, Kansas
  4. Overland Park, Kansas
  5. San Antonio, Texas
  6. Sherbrooke, Quebec
  7. Goteborg,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Knee OsteoarthritisSafety and Efficacy of Celecoxib Versus Naproxen in the 6-Month Treatment of Knee Osteoarthritis NCT00643799
  1. Montgomery, Alabama
  2. Phoenix, Arizona
  3. Tempe, Arizona
  4. Buena Park, California
  5. Paramount, California
  6. Rancho Mirage, California
  7. San Diego, California
  8. San Diego, California
  9. Denver, Colorado
  10. Washington, District of Columbia
  11. Clearwater, Florida
  12. Deland, Florida
  13. Jacksonville, Florida
  14. Miami, Florida
  15. Ocala, Florida
  16. Orlando, Florida
  17. Pembroke Pines, Florida
  18. Tampa, Florida
  19. Zephyrhills, Florida
  20. Rockford, Illinois
  21. Wichita, Kansas
  22. Wichita, Kansas
  23. Lexington, Kentucky
  24. Lexington, Kentucky
  25. Covington, Louisiana
  26. Metairie, Louisiana
  27. Clinton, Maryland
  28. Greenbelt, Maryland
  29. Hagerstown, Maryland
  30. Wheaton, Maryland
  31. Milford, Massachusetts
  32. Lansing, Michigan
  33. Flowood, Mississippi
  34. Kansas City, Missouri
  35. Lincoln, Nebraska
  36. Lincoln, Nebraska
  37. New York, New York
  38. Beachwood, Ohio
  39. Columbus, Ohio
  40. Columbus, Ohio
  41. Columbus, Ohio
  42. Oklahoma City, Oklahoma
  43. Bethlehem, Pennsylvania
  44. Duncansville, Pennsylvania
  45. Media, Pennsylvania
  46. Warwick, Rhode Island
  47. Austin, Texas
  48. Dallas, Texas
  49. San Angelo, Texas
  50. Salt Lake City, Utah
  51. Salt Lake City, Utah
ALL GENDERS
40 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE X-Ray Study Investigating The Safety And Efficacy Of SD-6010 In Subjects With Osteoarthritis Of The Knee
Official Title  ICMJE A Long-term, Confirmatory, Phase 3, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study To Investigate The Safety And Efficacy Of Orally Administered Sd-6010 In Subjects With Symptomatic Osteoarthritis Of The Knee
Brief Summary The objective of this 2-year study is to evaluate the safety, tolerability and disease modifying efficacy of SD 6010, an inhibitor of inducible nitric oxide synthase (iNOS). The efficacy of SD-6010 will be evaluated by radiography using joint space narrowing in the medial tibiofemoral compartment of the study knee as the primary endpoint.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Knee Osteoarthritis
Intervention  ICMJE
  • Drug: SD-6010
    200 mg tablets once a day for 2 years
  • Drug: SD-6010
    50 mg tablets once a day for 2 years
  • Drug: Placebo
    Placebo tablets once a day for 2 years
Study Arms  ICMJE
  • Active Comparator: 200 mg
    High dose active comparator
    Intervention: Drug: SD-6010
  • Active Comparator: 50 mg
    Low dose active comparator
    Intervention: Drug: SD-6010
  • Placebo Comparator: Placebo
    Placebo comparator to be used for control purposes
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Withdrawn
Actual Enrollment  ICMJE
 (submitted: January 24, 2012)		0
Original Estimated Enrollment  ICMJE
 (submitted: September 20, 2011)		1500
Estimated Study Completion Date  ICMJE December 2015
Estimated Primary Completion Date December 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Subjects aged >= 40 years Diagnosed with knee OA (ACR definition of OA) Radiographic evidence of OA in the study knee

Exclusion Criteria:

A diagnosis of any other rheumatic disease Current conditions in the study knee that would confound efficacy Selected, traditional clinical safety and laboratory parameters

Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 40 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01438918
Other Study ID Numbers  ICMJE A6171017
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP